Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
262.6 USD | -0.03% | -2.71% | -8.80% |
Apr. 17 | UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating | MT |
Apr. 16 | Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.80% | 141B | |
+27.97% | 672B | |
+23.98% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+2.32% | 211B | |
-0.25% | 203B | |
-11.81% | 144B | |
-4.23% | 113B |
- Stock Market
- Equities
- AMGN Stock
- News Amgen Inc.
- Amgen : Q2 Results Rise, Reaffirms Revenue, Adjusted Profit Outlook